Search
mavorixafor (Xolremdi)
Indications:
- treatment of Whim syndrome in patients >= 12 years of age
Mechanism of action:
- selective CXCR4 antagonist
- increases circulating neutrophils & lymphocytes to reduce risk of infection
General
hematologic agent
Database Correlations
PUBCHEM correlations
References
- Ingram I
FDA Approves First Drug for WHIM Syndrome
CXCR4 antagonist mavorixafor effectively boosts neutrophils and lymphocytes
to reduce infections.
https://www.medpagetoday.com/allergyimmunology/allergy/109871